H&M (Hennes & Mauritz) vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
Global fast-fashion giant with 4,100+ stores across 78 markets. Q1 2026 revenue up 3%; investing in AI personalization and sustainability initiatives.
About
H&M (Hennes & Mauritz) is a Swedish multinational fast-fashion retailer founded in 1947 by Erling Persson in Västerås, Sweden. Originally a women's clothing store named "Hennes" (Swedish for "Hers"), the company acquired hunting equipment and clothing brand Mauritz Widforss in 1968 and rebranded. Today H&M operates as one of the world's largest fashion retailers, with a core mission of delivering trend-forward clothing at accessible prices across a broad demographic.\n\nH&M's business spans 4,100+ stores across 78 markets along with a significant e-commerce presence. The company operates multiple brands under the H&M Group umbrella, including COS, ARKET, Weekday, & Other Stories, and Monki. H&M is investing heavily in AI-driven personalization tools to improve the online shopping experience and optimize inventory management. The value proposition centers on fast turnover of affordable, on-trend styles for men, women, and children.\n\nH&M generates approximately $23 billion in annual revenue. Q1 2026 revenue grew 3% year-over-year as the group continued its recovery from post-pandemic inventory challenges. The company faces ongoing pressure from ultra-fast fashion competitors like Shein and Temu, and is responding with sustainability commitments, AI personalization, and a tighter focus on its premium sub-brands to maintain differentiation and margin.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.